USD 0.92
(4.61%)
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2023 | 51.84 Million USD | -43.43% |
2022 | 90.22 Million USD | 22.46% |
2021 | 73.67 Million USD | 44.99% |
2020 | 50.81 Million USD | 3.62% |
2019 | 49.04 Million USD | 62.18% |
2018 | 30.24 Million USD | 13.78% |
2017 | 26.57 Million USD | -5.33% |
2016 | 28.07 Million USD | -1.86% |
2015 | 28.6 Million USD | 79.88% |
2014 | 15.9 Million USD | 81.87% |
2013 | 8.74 Million USD | -36.03% |
2012 | 13.66 Million USD | 0.0% |
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2024 Q1 | 10.88 Million USD | -22.55% |
2024 Q2 | 9.97 Million USD | -8.34% |
2023 Q2 | 14.51 Million USD | 24.32% |
2023 Q1 | 11.67 Million USD | -50.96% |
2023 FY | 51.03 Million USD | -43.43% |
2023 Q4 | 14.04 Million USD | 22.38% |
2023 Q3 | 11.48 Million USD | -20.9% |
2022 Q3 | 23.16 Million USD | 1.1% |
2022 Q4 | 23.8 Million USD | 2.76% |
2022 Q1 | 20.32 Million USD | -10.51% |
2022 FY | 90.22 Million USD | 22.46% |
2022 Q2 | 22.91 Million USD | 12.75% |
2021 Q2 | 17.5 Million USD | 28.32% |
2021 Q1 | 13.64 Million USD | -9.06% |
2021 Q4 | 22.71 Million USD | 14.65% |
2021 Q3 | 19.81 Million USD | 13.16% |
2021 FY | 73.67 Million USD | 44.99% |
2020 Q2 | 11.82 Million USD | -5.23% |
2020 Q3 | 11.51 Million USD | -2.66% |
2020 Q4 | 15 Million USD | 30.34% |
2020 FY | 50.81 Million USD | 3.62% |
2020 Q1 | 12.47 Million USD | -11.54% |
2019 FY | 49.04 Million USD | 62.18% |
2019 Q1 | 11.92 Million USD | 34.68% |
2019 Q3 | 11.75 Million USD | 4.47% |
2019 Q4 | 14.1 Million USD | 20.0% |
2019 Q2 | 11.25 Million USD | -5.64% |
2018 FY | 30.24 Million USD | 13.78% |
2018 Q4 | 8.85 Million USD | 39.08% |
2018 Q3 | 6.36 Million USD | -17.56% |
2018 Q2 | 7.72 Million USD | 5.82% |
2018 Q1 | 7.29 Million USD | 1.0% |
2017 Q1 | 6.08 Million USD | 6.76% |
2017 Q2 | 6.8 Million USD | 11.99% |
2017 Q3 | 6.46 Million USD | -5.08% |
2017 Q4 | 7.22 Million USD | 11.79% |
2017 FY | 26.57 Million USD | -5.33% |
2016 Q4 | 5.69 Million USD | -15.88% |
2016 Q1 | 7.27 Million USD | -13.92% |
2016 Q3 | 6.77 Million USD | -18.75% |
2016 Q2 | 8.33 Million USD | 14.51% |
2016 FY | 28.07 Million USD | -1.86% |
2015 Q2 | 6.55 Million USD | 1.64% |
2015 Q1 | 6.45 Million USD | 36.47% |
2015 FY | 28.6 Million USD | 79.88% |
2015 Q3 | 7.6 Million USD | 15.92% |
2015 Q4 | 8.45 Million USD | 11.21% |
2014 FY | 15.9 Million USD | 81.87% |
2014 Q2 | 4.07 Million USD | 61.44% |
2014 Q3 | 4.52 Million USD | 10.94% |
2014 Q4 | 4.72 Million USD | 4.49% |
2014 Q1 | 2.52 Million USD | 5.65% |
2013 Q3 | 2.19 Million USD | 14.29% |
2013 FY | 8.74 Million USD | -36.03% |
2013 Q4 | 2.39 Million USD | 9.13% |
2013 Q1 | 2.24 Million USD | 0.0% |
2013 Q2 | 1.91 Million USD | -14.61% |
2012 FY | 13.66 Million USD | 0.0% |
Name | Operating Expenses | Operating Expenses Difference |
---|---|---|
Bright Green Corporation | 8.25 Million USD | -528.242% |
Alpha Teknova, Inc. | 45.85 Million USD | -13.06% |
ANI Pharmaceuticals, Inc. | 195.98 Million USD | 73.545% |
Aquestive Therapeutics, Inc. | 44.85 Million USD | -15.593% |
Collegium Pharmaceutical, Inc. | 159.2 Million USD | 67.434% |
Cosmos Health Inc. | 26.18 Million USD | -98.038% |
Journey Medical Corporation | 54.59 Million USD | 5.03% |
Embecta Corp. | 528.4 Million USD | 90.188% |
Esperion Therapeutics, Inc. | 271.89 Million USD | 80.931% |
Dynavax Technologies Corporation | 219.14 Million USD | 76.341% |
Intra-Cellular Therapies, Inc. | 590 Million USD | 91.212% |
Pacira BioSciences, Inc. | 326.37 Million USD | 84.114% |
PainReform Ltd. | 9.58 Million USD | -440.985% |
Sunshine Biopharma, Inc. | 13.12 Million USD | -295.048% |
Sunshine Biopharma, Inc. | 13.12 Million USD | -295.048% |
Safety Shot Inc | 12.1 Million USD | -328.153% |
China SXT Pharmaceuticals, Inc. | 3.06 Million USD | -1589.307% |
Procaps Group, S.A. | 199.47 Million USD | 74.008% |
Theratechnologies Inc. | 72.75 Million USD | 28.737% |
Harrow Health, Inc. | 89.97 Million USD | 42.374% |
Sonoma Pharmaceuticals, Inc. | 9.44 Million USD | -448.888% |
Biofrontera Inc. | 39.95 Million USD | -29.753% |
DURECT Corporation | 43.71 Million USD | -18.605% |
Supernus Pharmaceuticals, Inc. | 529.01 Million USD | 90.199% |
Cronos Group Inc. | 96.7 Million USD | 46.388% |
OptiNose, Inc. | 85.1 Million USD | 39.075% |
Ironwood Pharmaceuticals, Inc. | 232.12 Million USD | 77.664% |
Kala Pharmaceuticals, Inc. | 39.15 Million USD | -32.424% |
RedHill Biopharma Ltd. | -9.56 Million USD | 642.286% |
Organogenesis Holdings Inc. | 314.13 Million USD | 83.495% |
Guardion Health Sciences, Inc. | 9.73 Million USD | -432.822% |
Cumberland Pharmaceuticals Inc. | 43.04 Million USD | -20.463% |
Radius Health, Inc. | 265.92 Million USD | 80.503% |
Universe Pharmaceuticals INC | 13.84 Million USD | -274.573% |
ProPhase Labs, Inc. | 37.85 Million USD | -36.976% |
Phibro Animal Health Corporation | 260.29 Million USD | 80.081% |
Procaps Group S.A. | 187.24 Million USD | 72.31% |
Alvotech | 285.43 Million USD | 81.836% |
TherapeuticsMD, Inc. | 9.82 Million USD | -427.715% |
Viatris Inc. | 5.96 Billion USD | 99.131% |
Rockwell Medical, Inc. | 15.37 Million USD | -237.245% |
Aytu BioPharma, Inc. | 59.84 Million USD | 13.356% |
SIGA Technologies, Inc. | 22.04 Million USD | -135.213% |
Tilray Brands, Inc. | 251.35 Million USD | 79.373% |
Lifecore Biomedical, Inc. | 49.03 Million USD | -5.73% |
Shineco, Inc. | 17.94 Million USD | -188.878% |
PetIQ, Inc. | 192.72 Million USD | 73.097% |
Regencell Bioscience Holdings Limited | 3.99 Million USD | -1199.078% |
Incannex Healthcare Limited | 30.05 Million USD | -72.522% |
Neurocrine Biosciences, Inc. | 1.59 Billion USD | 96.752% |
Alimera Sciences, Inc. | 62.64 Million USD | 17.23% |
Silver Spike Investment Corp. | 762.49 Thousand USD | -6699.809% |
Assertio Holdings, Inc. | 368.58 Million USD | 85.933% |
Shuttle Pharmaceuticals Holdings, Inc. | 5.88 Million USD | -780.934% |
Petros Pharmaceuticals, Inc. | 17.8 Million USD | -191.141% |
Clever Leaves Holdings Inc. | 21.16 Million USD | -144.924% |
Cyclo Therapeutics, Inc. | 21.04 Million USD | -146.401% |
Avadel Pharmaceuticals plc | 164.96 Million USD | 68.57% |
Hempacco Co., Inc. | 7.59 Million USD | -582.529% |
Talphera, Inc. | 11.99 Million USD | -332.283% |
Alvotech | 285.43 Million USD | 81.836% |
Eagle Pharmaceuticals, Inc. | 140.71 Million USD | 63.154% |
Lantheus Holdings, Inc. | 344.9 Million USD | 84.967% |
Currenc Group, Inc. | 24 Million USD | -116.015% |
Kamada Ltd. | 45.42 Million USD | -14.137% |
Indivior PLC | 911 Million USD | 94.309% |
Evoke Pharma, Inc. | 12.4 Million USD | -317.804% |
Flora Growth Corp. | 10.57 Million USD | -390.103% |
Cyclo Therapeutics, Inc. | 21.04 Million USD | -146.401% |
Evolus, Inc. | 189.75 Million USD | 72.677% |
HUTCHMED (China) Limited | 436.23 Million USD | 88.115% |
Amphastar Pharmaceuticals, Inc. | 154.13 Million USD | 66.362% |
Akanda Corp. | 3.48 Million USD | -1388.385% |